. 2017 Aug 31;38(11):1147–1154. doi: 10.1093/carcin/bgx084

Table 1.

Summary of discovery and validation studies for rs174548

Phase	Study	EA^a	OA^b	EAF^c		Allele frequency^d		OR (95% CI)	P ^e
Phase	Study	EA^a	OA^b	Case	Control	Case	Control	OR (95% CI)	P ^e
Discovery	NJMU(Nanjing)	G	C	0.37	0.41	192.0/702.0/579.0	331.0/943.0/688.0	0.89(0.79–0.99)	3.34E−02
	NJMU(Beijing)	G	C	0.34	0.41	109.0/369.0/380.0	182.0/545.0/388.0	0.71(0.62–0.82)	1.46E−06
Validation I	NJMU Validation (Nanjing)	G	C	0.35	0.40	74.0/370.0/293.0	124.0/352.0/273.0	0.81(0.69–0.96)	1.22E−02
	NJMU Validation (Beijing)	G	C	0.30	0.38	150.0/630.0/734.0	234.0/669.0/571.0	0.68(0.60–0.76)	1.25E−11
Validation II	MDACC	G	C	0.31	0.33	99.9/510.0/540.1	124.1/507.8/502.1	0.89(0.77–1.00)	4.67E−02
	FLCCA	G	C	0.40	0.43	858.3/2133.7/1804.0	731.1/1738.3/1271.6	0.91(0.85–0.97)	4.90E−03
	NCI	G	C	0.30	0.31	516.0/2424.3/2775.7	582.9/2433.4/2804.7	0.93(0.87–0.98)	1.18E−02
META		G	C					0.87(0.84–0.90)	1.76E−`15

^aEffect allele.

^bOther allele.

^cEffect allele frequency.

^dEA homozygote/heterozygote/OA homozygote.

^eAdjusted by age, gender, smoking status (or py) and PC(s).